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Background: Evidence on the association between antibiotic use and combined oral contraceptive (COC) failure is controversial. We
examined the effect of concomitant antibiotic treatment on the risk of breakthrough pregnancy among COC users.
Study Designs:We performed a case-crossover study of 1330 COC failure cases among 17,721 women from the Slone Epidemiology Center
Birth Defects Study (1997–2008) and among 25,941 women from the National Birth Defects Prevention Study (NBDPS, 1997–2005). Self-
matched odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by comparing antibiotic use between the 4 weeks before
conception (“case period”) and the 4–8 weeks before conception (“control period”) using conditional logistic regression. A case–time-control
analysis was conducted using nonusers of COCs with unplanned pregnancies as controls.
Results: For the combined data, the self-matched OR was 1.08 (95% CI: 0.63–1.84) and the case–time-control OR was 1.12 (0.63–1.98) for
antibiotics overall. The results did not appreciably differ when adjusted for characteristics that might vary between the case and control
period. However, among COC failure cases from the NBDPS, allowing a 1-month gap between the case and control period resulted in a self-
matched OR of 1.45 (0.85–2.50) and a case–time-control OR of 1.55 (0.86–2.79) for antibiotics overall.
Conclusions: We did not find an association between concomitant antibiotic use and the risk of breakthrough pregnancy among COC users.
However, due to limited power and potential carryover effects, findings from this study cannot rule out an elevated risk of COC failure
among antibiotic users.
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Studies have shown that the antibiotic rifampin is
associated with a higher risk of unintended pregnancy
among combined oral contraceptive (COC) users by
inducing hepatic microsomal enzymes that decrease steroid
hormone plasma levels [1–4]. However, whether other
antibiotics interfere with the effectiveness of COCs is
controversial. Some have suggested that broad-spectrum
antibiotics (e.g., ampicillin) might decrease hormone plasma
levels by interfering with the enterohepatic recirculation of
hormone metabolites through a disruption of the intestinal
bacterial flora [1–3]. Although package inserts of both
broad-spectrum antibiotics and COCs warn of potential COC
419S. Toh et al. / Contraception 83 (2011) 418–425failure with concomitant antibiotic use, it has been argued
that antibiotics other than rifampin do not seem to
significantly affect plasma levels of COC steroids, and
women taking COCs and antibiotics concomitantly do not
appear to have a greater risk of breakthrough pregnancy.
Given the serious consequences of unwanted pregnancies, it
is critical to resolve this important source of confusion.
We conducted a study to assess the effect of concomitant
antibiotic use on COC failure. The study also illustrated the
application of case-only self-matched study design in the
studies of drug–drug interactions [5] when the use of one of
the drugs is transient.2. Methods
2.1. Data source
We used data from the Slone Epidemiology Center Birth
Defects Study (BDS) and the National Birth Defects
Prevention Study (NBDPS). These two multicenter case-
control surveillance programs of birth defects represent the
largest interview-based data sources on prenatal exposure
and birth defect outcomes in the United States. The BDS has
been approved by the relevant institutional review boards at
Boston University and participating hospitals; the NBDPS
has been approved by the institutional review boards of CDC
and the participating study centers.
Since 1976, the BDS has interviewed more than 37,000
mothers of babies with and without birth defects from the
greater metropolitan areas of Philadelphia, San Diego and
Toronto, as well as from selected regions in Iowa,
Massachusetts and New York State [6,7]. Study subjects
are identified through review of admissions and discharges at
major birth hospitals and pediatric referral hospitals and
clinics, logbooks in newborn intensive care units, through
weekly telephone contact with collaborators at newborn
nurseries in community hospitals and through collaborations
with state birth defects registries. Mothers provide informed
consent before participation.
The NBDPS, established in 1997, is an on ongoing
population-based, case-control study. The 10 participating
sites (Arkansas, California, Georgia, Iowa, Massachusetts,
New Jersey, New York, North Carolina, Texas and Utah)
identify cases with any of approximately 30 birth defects from
birth defect surveillance systems and a random sample of non-
malformed controls from birth certificates or hospital records.
The NBDPS has been described in detail elsewhere [8].
In the BDS, mothers who agree to participate were
interviewed within 6 months of delivery, while in the NBDPS,
the interview window was between 6 weeks and 24 months of
delivery. The sampling scheme of the BDS and the NBDPS
ensures that no woman is included in both studies.
In both BDS and NBDPS, mothers were interviewed by
trained interviewers using a computer-assisted telephone
interview. The interview, which takes about 1 h to complete
and can be conducted in either English or Spanish, collectsinformation on demographics, lifestyle factors, dietary
intake, occupational exposure, reproductive factors, preg-
nancy planning and medical factors. Although some women
did not respond to it, a question about whether the pregnancy
was intended is asked in both studies. Specifically, the BDS
asks, “At the time that you became pregnant, did you
(a) want to become pregnant then, (b) did you want to wait
until later, or (c) did you not want to become pregnant at
all?”; the NBDPS asks, “At the time you became pregnant
with (index baby), did you want to become pregnant then,
did you want to wait until later, or did you not want to
become pregnant at all?”
The interview also includes detailed questions about use
of medications (prescription, over-the-counter, vitamins/
minerals and herbal products) that occurred from 2 months
before the last menstrual period (in the BDS) or from 3
months before conception (in the NBDPS) through the end
of the pregnancy. Medications are coded by means of the
Slone Drug Dictionary (http://slone-web.bu.edu/slonedrug-
dictionary). When possible, reported medications are
verified by asking the woman to read information from the
medication container. Identification of timing of drug
exposure is facilitated by use of a calendar covering periods
before and after pregnancy; special dates (e.g., last menstrual
period, holidays) are marked to help enhance recall. Data are
also collected on duration, frequency, indication, form and
number of pills per day.
2.2. Study population
We identified 17,721 women interviewed in BDS from
1997 to 2008 and 25,941 in NBDPS from 1997 to 2005. A
total of 1330 (387 from the BDS, 943 from the NBDPS)
reported the pregnancies were unplanned and were using
COCs to prevent pregnancy during the month before and at
least part of the month after their estimated date of
conception (i.e., 14 days after the last menstrual period).
These women were considered cases of COC failure under
the assumption that they were taking COCs continuously but
still had a breakthrough pregnancy. The results (not shown)
were materially unchanged when we modified the definition
of COC failure cases by requiring women to use COCs from
the month before to at least part of the second month after
their estimated date of conception. Users of progestin-only
OCs were excluded from the study.
2.3. Statistical analysis
Because both studies were restricted to women who had
been pregnant, we did not have data on women who used
COCs, with or without concomitant antibiotic therapy, who
did not become pregnant. Therefore, we could not estimate
the rate ratio of pregnancy (i.e., rate ratio of COC failure)
associated with antibiotic use among COC users by
comparing pregnancy rates among women exposed and not
exposed to antibiotics. Instead, we used a case-crossover
design, where cases served as their own controls (Fig. 1),
Fig. 1. A case-crossover design for concomitant antibiotic use and COC failure. COC failure cases were women who used COCs during the month before and
the month after the estimated date of conception. Each line represents a woman; the lines illustrate a sample of possible COC and antibiotic use patterns
around conception.
420 S. Toh et al. / Contraception 83 (2011) 418–425to examine whether antibiotic use before the time of
breakthrough pregnancy was significantly different from
the usual frequency among women with COC use [9,10]. In
doing so, we evaluated the prevalence of antibiotic use
during the 4 weeks preceding the date of conception (“case
period”), which is presumably the period when antibiotics
might be most likely to affect the risk of breakthrough
pregnancy, and compared it with the 4–8 weeks before the
date of conception (“control period”), which provided an
estimate of the expected prevalence of antibiotic use for each
case. Using conditional logistic regression, we estimated a
self-matched odds ratio (OR) by the ratio of the discordant
pairs, i.e., the ratio of the number of women exposed only
during the case period to the number of women exposed only
during the control period.
The case-crossover approach effectively eliminates po-
tential confounding effects from both measured and
unmeasured subject characteristics that are constant during
the case and control period (e.g., sociodemographic and
genetic factors), but does not adjust by design for time-
varying factors [9,10]. We used multivariable conditional
logistic regression models to adjust for confounding by
transient factors potentially associated with both the use of
antibiotics and conception (e.g., infections). We assumed no-
carryover effect and that the underlying subject-specific
probability of being exposed to antibiotics among COC users
was constant within the interval between the control and the
case period.To account for the potential time trends in antibiotic use
between the case and control period, we performed a case–
time-control analysis [10,11] using as a control group 16,896
(5941 from the BDS, 10,955 from the NBDPS) non-COC
users with unplanned pregnancies. We estimated the
expected time trends of antibiotic use around conception
among COC failure cases using the information from the
control women through a self-matched OR for antibiotic use.
We removed the potential effect of time from the case-
crossover effect estimate by dividing the OR obtained among
COC failure cases by the OR obtained in the control group,
assuming that the control women provide an unbiased
estimate of such trend for the cases [10–12].
To examine the assumption of no-carryover effect, we used
data from NBDPS where history of medication use is collected
up to 3 months before conception (in contrast to the 2-month
window prior to the last menstrual period used by the BDS); the
control period was defined as the third month prior to the
conception in this analysis, therefore leaving a “wash-out” gap
of 1 month between the case and control period.
Whenever possible, we repeated our analysis by antibiotic
class (e.g., macrolides), indications for antibiotic therapy
(e.g., urinary tract infection), cigarette smoking (never/ever),
alcohol drinking (never/ever) and pre-pregnancy body mass
index (b25 and≥25 kg/m2). We did not stratify by dosage of
estrogen component in COCs because the large majority of
women in both studies had a low-dose regimen. Also,
because most antibiotics used by study women were
421S. Toh et al. / Contraception 83 (2011) 418–425considered broad-spectrum, we did not estimate the effects
of broad- and narrow-spectrum antibiotics separately.
Finally, since recall of medication use may differ across
periconceptional months (e.g., women may be particularly
aware of their medication use around conception), we also
estimated the effect of acetaminophen and ibuprofen, often
used concomitantly with antibiotics but not thought to be
associated with the risk of COC failure.3. Results
The baseline characteristics for COC failure cases and
non-OC users with unplanned pregnancies are shown in
Table 1. Compared to non-OC users with unplanned
pregnancies, women with breakthrough pregnancies while
taking COCs were in general younger, more likely to be non-
Hispanic white, had a lower education level, more likely to
be obese and more likely to smoke or drink alcohol. These
differences were observed in both BDS and NBDPS, and in
the combined population.
Among women with COC failure, the prevalence of
antibiotic use was 3.6% during the 4 weeks before the date of
conception (case period) and 3.9% during the 4–8 weeks
preceding the date of conception (control period) in the BDS;Table 1
Baseline characteristics for COC failure cases and non-OC users with unplanned
Characteristics The Slone Epidemiology











b20 49 (12.7) 797 (13.4) 176 (18.7)
20–24 125 (32.3) 1293 (21.8) 315 (33.4)
25–29 115 (29.7) 1323 (22.3) 238 (25.2)
30–34 61 (15.8) 1355 (22.8) 154 (16.3)
≥35 37 (9.6) 1153 (19.4) 60 (6.4)
Unknown 0 (0.0) 20 (0.3) 0 (0.0)
Maternal race/ethnicity
Non-Hispanic white 267 (69.0) 3363 (56.6) 560 (59.4)
Hispanic 57 (14.7) 1161 (19.5) 216 (22.9)
Non-Hispanic black 45 (11.6) 907 (15.3) 120 (12.7)
Other 18 (4.7) 506 (8.5) 45 (4.8)
Unknown 0 (0.0) 4 (0.1) 2 (0.2)
Maternal education (years)
≤12 155 (40.1) 2761 (46.5) 435 (46.1)
13–15 136 (35.1) 1532 (25.8) 339 (36.0)
N15 96 (24.8) 1641 (27.6) 154 (16.3)
Unknown 0 (0.0) 7 (0.1) 15 (1.6)
Pre-pregnancy body mass index
b18.5 19 (4.9) 323 (5.4) 70 (7.4)
18.5–24.9 214 (55.3) 3238 (54.5) 462 (49.0)
25.0–29.9 83 (21.5) 1289 (21.7) 195 (20.7)
≥30.0 65 (16.8) 928 (15.6) 188 (19.9)
Unknown 6 (1.6) 163 (2.7) 28 (3.0)
Cigarette smoking 217 (56.1) 2788 (47.0) 375 (39.8)
Alcohol intake 189 (48.8) 2462 (41.1) 476 (50.5)the corresponding prevalence was 4.1% and 3.8% in the
NBDPS (Fig. 2). When the two data sources were combined,
the prevalence of antibiotic use was 4.0% during the case
period and 3.8% during the control period. More than 80% of
the antibiotics had a treatment duration of 14 days or less.
Amoxicillin and ampicillin were the most commonly used
antibiotics, followed by macrolides and sulfonamides.
Although there were some variations between the
prevalence of periconceptual antibiotic use in the BDS and
NBDPS, there was no evidence that the results differed by
the two data sources (p value of test for heterogeneity of ORs
was N.05); we therefore combined data from the BDS and
NBDPS to provide more robust estimates (Table 2). Among
women with COC failure, 28 had used antibiotics only
during the case period and 26 only during the control period,
giving a self-matched OR of 1.08 (95% CI: 0.63–1.84). For
specific antibiotics, only ampicillin/amoxicillin had at least
five discordant pairs in each of the case (18 discordant pairs)
and control period (15 discordant pairs), with an OR of 1.20
(0.60–2.38). Due to small sample sizes, the effects of other
specific antibiotics were not further explored.
When we adjusted for occurrence of urinary tract
infection and upper respiratory tract infection, which might
change between the case and control period, the OR was 1.10













2291 (20.9) 225 (16.9) 3088 (18.3)
2929 (26.7) 440 (33.1) 4222 (25.0)
2588 (23.6) 353 (26.5) 3911 (23.2)
1993 (18.2) 215 (16.2) 3348 (19.8)
1153 (10.5) 97 (1.3) 2306 (13.7)
1 (0.0) 0 (0.0) 21 (0.1)
5709 (52.1) 827 (62.2) 9072 (53.7)
2707 (24.7) 273 (20.5) 3868 (22.9)
1608 (14.7) 165 (12.4) 2515 (14.9)
887 (8.1) 63 (4.7) 1393 (8.2)
44 (0.4) 2 (0.2) 48 (0.3)
5630 (51.4) 590 (44.4) 8391 (49.7)
2858 (26.1) 475 (35.7) 4390 (26.0)
2192 (20.0) 250 (18.8) 3833 (22.7)
275 (2.5) 15 (1.1) 282 (1.7)
692 (6.3) 89 (6.7) 1015 (6.0)
5404 (49.3) 676 (50.8) 8642 (51.2)
2370 (21.6) 278 (20.9) 3659 (21.7)
1952 (17.8) 253 (19.0) 2880 (17.1)
537 (4.9) 34 (2.6) 700 (4.1)
4239 (38.7) 592 (44.5) 7027 (41.6)
5176 (47.3) 665 (50.0) 7638 (45.2)
Table 2
The association between antibiotic use and the risk of COC failure
No gap between case
and control perioda
The Slone Epidemiology


















Antibiotic overall 8/9 0.89 (0.34–2.30) 20/17 1.18 (0.62–2.25) 28/26 1.08 (0.63–1.84)
Amoxicillin/ampicillin 6/4 1.50 (0.42–5.32) 12/11 1.09 (0.48–2.47) 18/15 1.20 (0.60–2.38)
Acetaminophen 8/14 0.57 (0.24–1.36) 27/30 0.90 (0.54–1.51) 35/44 0.80 (0.51–1.24)















Antibiotic overall 1.07 0.84 (0.30–2.35) 0.93 1.26 (0.64–2.51) 0.96 1.12 (0.63–1.98)
Amoxicillin/ampicillin 1.23 1.22 (0.31–4.88) 0.97 1.13 (0.46–2.74) 1.04 1.16 (0.55–2.45)
Acetaminophen 0.81 0.71 (0.29–1.75) 1.56 0.61 (0.36–1.02) 1.27 0.65 (0.41–1.01)
Ibuprofen 0.58 1.04 (0.24–4.52) 0.77 0.66 (0.30–1.48) 0.71 0.75 (0.37–1.52)
A 1-month gap between
case and control periodb
The Slone Epidemiology


















Antibiotic overall – – 32/22 1.45 (0.85–2.50) – –
Amoxicillin/ampicillin – – 17/11 1.55 (0.72–3.30) – –
Acetaminophen – – 32/25 1.28 (0.76–2.16) – –















Antibiotic overall – – 0.94 1.55 (0.86–2.79) – –
Amoxicillin/ampicillin – – 0.92 1.69 (0.74–3.83) – –
Acetaminophen – – 1.55 0.84 (0.50–1.42) – –
Ibuprofen – – 0.73 0.90 (0.44–1.83) – –
a Case period: the 4 weeks preceding the date of conception; control period: the 4–8 weeks before the date of conception.
b Case period: the 4 weeks preceding the date of conception; control period: the 8–12 weeks before the date of conception.
Fig. 2. Use of antibiotics around the months of conception among COC failure cases and non-OC users with unplanned pregnancies. COC failure cases were
women who used COCs during the month before and the month after the estimated date of conception. The Slone Epidemiology Center Birth Defects Study
(1997–2008) and the National Birth Defects Prevention Study (1997–2005).
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were associated with COC failure, nor did we observe the
effects of antibiotics varied by cigarette smoking, alcohol
drinking and pre-pregnancy body mass index (results not
shown), but our power to detect such effect modification
was small.
In the case–time-control analysis, the OR for time trends
of overall antibiotic use was 0.96 (0.79–1.18) in control
women (non-OC users who did not plan to become
pregnant). We divided the case-crossover OR by this OR
and obtained a case–time-control OR of 1.12 (0.63–1.98).
The OR for time trends of ampicillin/amoxicillin was 1.04
(0.77–1.39), resulting in a case–time-control OR of 1.16
(0.55–2.45).
To examine the assumption of no-carryover effect, we
used data from NBDPS where history of medication use is
collected up to 3 months before conception. When we
allowed for a 1-month gap between the case and control
period in the COC failure cases from the NBDPS, the OR
was 1.45 (0.85–2.50) for overall antibiotics and 1.55 (0.72–
3.30) for ampicillin/amoxicillin (Table 2). Adjusting for
occurrence of urinary tract infection and upper respiratory
tract infection did not materially change the results. In the
case–time-control analysis, the OR for time trends of overall
antibiotic use was 0.94 (0.76–1.17); after adjusting for this
time trend, the case–time-control OR was 1.55 (0.86–2.79).
The OR for time trends of ampicillin/amoxicillin use was
0.92 (0.67–1.25); after adjusting for this time trend, the
case–time-control OR was 1.69 (0.74–3.83).
Neither acetaminophen nor ibuprofen use was associated
with an increased risk of COC failure. In the analysis without
a gap between the case and control period, the OR was 0.80
(0.51–1.24) for acetaminophen and 0.52 (0.26–1.05) for
ibuprofen; the case–time-control OR was 0.65 (0.41–1.01)
for acetaminophen and 0.75 (0.37–1.52) for ibuprofen.
When we allowed a 1-month gap between the case and
control period among COC failure cases from the NBDPS,
the OR was 1.28 (0.76–2.16) for acetaminophen and 0.65
(0.32–1.31) for ibuprofen. After adjusting for time trends,
the case–time-control OR was 0.84 (0.50–1.42) for
acetaminophen and 0.90 (0.44–1.83) for ibuprofen.4. Discussion
In this case-crossover study, the OR between antibiotic
use and the risk of breakthrough pregnancy during the month
following treatment was 1.08 (95% CI: 0.63–1.83) when we
used the preceding month as the control window. Allowing a
gap of 1 month between the case and control windows in a
subgroup of women participating in the NBDPS resulted in
an OR of 1.45 (0.85–2.50). None of the analyses reached
statistical significance at the .05 level. To our knowledge,
this is the largest study to examine this topic.
The purported mechanism of breakthrough pregnancy
associated with concomitant antibiotic use primarilyinvolves enterohepatic recirculation of COCs. In the liver,
ethinyl estradiol, the estrogen component in most COCs, is
metabolized to form inactive conjugates, which are then
excreted in the bile [1–4]. However, enzymatic activity of
intestinal bacterial flora can break down these conjugates,
releasing active ethinyl estradiol for reabsorption. Broad-
spectrum antibiotics may disrupt the gut bacterial flora,
leading to a decrease in intestinal reabsorption of COCs and
a consequent reduction in circulating levels of COCs
required to achieve contraception. Other proposed mechan-
isms include antibiotic-associated interference in absorption,
increase in excretion, alterations in plasma-protein binding
of COCs and, at least for rifampin, induction of hepatic
microsomal enzyme [1–3].
Evidence of the association, or lack thereof, between
antibiotics and COC failure has largely come from individual
case reports, case series and spontaneous adverse reaction
reports; pharmacokinetic studies with very small number of
subjects; and small observational studies of primarily long-
term antibiotic users. Case series and spontaneous adverse
reaction reports suggesting such an association often lack an
appropriate control group [13,14]. Pharmacokinetic studies
do not appear to support an effect of antibiotics on the
plasma levels of COCs (except for rifampin), but a number of
studies have suggested that some women might be more
susceptible to an antibiotic-induced decrease in plasma
concentration of COCs [1–3]. Several clinical studies have
found higher risks of pregnancies among COC users with
concomitant antibiotic therapy when compared to those
without concomitant use [15] or to external controls [16,17],
but these higher risks were still within a ‘normal’ range of 1–
3% found in typical COC users. In addition, these studies
largely included patients from dermatology clinics [15–17],
and their findings may not be applicable to other patients.
The ideal design to assess a causal effect of antibiotics on
COC failure would be infeasible and unethical, as it would
involve randomizing thousands of COC users to antibiotics
and studying COC failures without adding further contra-
ceptive protection. Even in a hypothetical large observation-
al cohort study with detailed monitoring of COC and
antibiotic use and recording of timing of conception,
evaluation of COC failure could be biased by residual
confounding due to factors associated with both infections
and breakthrough pregnancy, including socioeconomic
determinants, sexual behavior, compliance with treatments,
and physiologic characteristics. A case-control study could
compare antibiotic exposure in COC failure cases with a
control group of COC users who did not get pregnant. This
design could still be biased because these two distinct groups
of women may differ in measured and unmeasured
characteristics that could confound the results.
Comparing the pattern of antibiotic use between two
periods in the same women may offer several advantages
over the more conventional approach. The self-matched
design effectively avoids control (subject) selection bias and
any confounding factors that remain unchanged during the
424 S. Toh et al. / Contraception 83 (2011) 418–425few months around conception. A case-crossover study is
particularly appropriate for our study because such design
has the greatest utility in studies of intermittent exposures
with immediate and transient effects on abrupt outcomes
[9,18]. In this study, more than 80% of antibiotic treatments
were short-term (14 days or less), and studies have shown
that antibiotic-associated changes in fecal flora are normally
reversed by 10–14 days after stopping of treatment [19,20].
Several limitations need to be addressed, however. First,
the assumption of no-carryover effect might be violated
because we did not allow for a large enough gap between the
case and control period in the primary analysis. To examine
the robustness of our results, we created a 1-month “wash-
out” gap between the case and control period in the subset of
COC failure cases interviewed in the NBDPS and observed a
higher OR. Whether this reflected the sensitivity of our
findings to the selection of control period warrants further
investigation. Second, the assumption of constant frequency
of antibiotic use during the 8 weeks before conception
among COC users might be violated if there were such a
trend. After accounting for potential time trends of antibiotic
use, the case–time-control OR suggested a higher risk,
although the 95% CI still included one.
Third, although the self-matching adjusts for between-
person confounding by design, characteristics that change
during the 8 weeks before conception within person and that are
associated with antibiotics use (e.g., frequency of sexual
intercourse and infections, concomitant medications) might still
confound the association between antibiotics and COC failure.
The results in the pooled analysis were similar when we
adjusted for factors that might vary over time. Nonetheless, it is
possible that other events occurring just prior to conception, but
which were not considered in our analysis, might have led to a
lower use of antibiotics and an underestimation of the effect, as
suggested by lower than expected ORs of acetaminophen and
ibuprofen. While a close temporal proximity between the case
and control period reduced the potential for time trends in
antibiotic use and changes in women's characteristics that
might confound our findings, it also introduced a high
correlation of antibiotic use between two periods — which
might partially explain why we observed an effect closer to the
null. Fourth, our analyses might have excluded COC failure
cases that resulted in pregnancy termination. Such exclusion
would affect our results if COC failures associated antibiotic
use had a higher or lower probability to be terminated than other
COC failures. Fifth, many of the so-called COC failures might
be due to missing pills. Restricting the analysis to breakthrough
pregnancies among women with perfect compliance (some-
thing we could not do in this study) might result in different OR
estimates for concomitant antibiotic use.
One of the main strengths of the current study is the
access to data on real use of COCs and on date of last
menstrual period based mostly on first trimester ultrasound.
Electronic health care databases that contain prescriptions or
dispensing claims for medications may be less suited to
study the effect of antibiotic use on COC failure because thenarrow risk window requires accurate information on
exposure status around conception. These databases are
prone to exposure misclassification because they often lack
information needed to determine the date of conception, such
as gestational age at birth and last menstrual period [21].
Additionally, electronic prescribing and dispensing infor-
mation may not accurately reflect whether or when the
women took their pills relative to the time of conception.
Date of conception and time of COC discontinuation are
critical for evaluating failure. On the other hand, information
bias due to imperfect recall of medication use around
conception is often an issue in interview-based studies.
Although women would probably remember if they got
pregnant while on the pill, their recall of timing of antibiotic
use in relation to the date of conception might be inaccurate,
which would tend to dilute the associations under most
scenarios. The case-only design is not affected by differential
recall among case and control subjects since it compares two
time periods within the same subject. However, there could
be recall bias due to differential recall of antibiotic use over
time around conception. This might lead to over- or
underestimation of antibiotic use in the case or control
period, and could bias our results in either direction.
In conclusion, we did not find an association between
concomitant antibiotic use and the risk of breakthrough
pregnancy among COC users. This study cannot rule out an
increased risk of COC failure with concurrent antibiotic use
due to its limited power, but the data support the
pharmacokinetic and pharmacodynamic data of limited
effect of antibiotics on contraceptive steroid metabolism.Acknowledgment
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